Adalvo and Jiangsu Hansoh Pharma, a leading R&D-driven pharmaceutical company in China, are pleased to announce that they have entered into an strategic partnership for the commercialization of Fulvestrant pre-filled injection in all EU markets and select Asia-Pacific markets.
The product is a fully EU compliant generic version of Faslodex®, which is a widely used drug, indicated in estrogen receptor positive, locally advanced, or metastatic breast cancer, in postmenopausal women. This product compliments Adalvo's broad oncology portfolio and creates additional synergies for our existing partners in the market.
As part of this partnership, Hansoh will be delivering an EU dossier which has already been submitted and is undergoing regulatory revision via an on-going DCP procedure, while Adalvo will be taking on commercialization responsibilities.
While Fulvestrant generics are available in Europe, Adalvo and its partners believe that leveraging on an on-going DCP filing, and competitive manufacturing of the product, combined with Adalvo's wide network of strategic partners, in the above mentioned regions, will be the basis for a solid a product launch.